LDL cholesterol is associated with small abdominal aortic aneurysms

European Journal of Vascular and Endovascular Surgery

Volumn 26, Issue 6, 2003, Pages 618-622

  Hobbs, S D ^a   Claridge, M W C ^a   Quick, C R G ^b   Day, N E ^c   Bradbury, A W ^a   Wilmink, Antonius B M ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^b HINCHINGBROOKE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Abdominal aortic aneurysm; LDL cholesterol

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ABDOMINAL AORTA ANEURYSM; ADULT; AGE; AGED; ANAMNESIS; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY HEIGHT; BODY WEIGHT; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FAMILY HISTORY; HUMAN; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RISK FACTOR; SCREENING TEST; SMOKING; STATISTICAL MODEL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0344034238     PISSN: 10785884     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-5884(03)00412-X     Document Type: Article

References (36)

1. National service framework for coronary heart disease. London: Department of Health, 2002.
2. Burns P, Gough S, Bradbury AW. Management of peripheral arterial disease in primary care. BMJ 2003; 326: 584-588.
3. Wilmink AB, Quick CR. Epidemiology and potential for prevention of abdominal aortic aneurysm. Br J Surg 1998; 85(2): 155-162.
4. Reed D, Reed C, Stemmerman G, Hayashi T. Are aortic aneurysms caused by atherosclerosis? Circulation 1992; 85: 205-211.
5. Krohn CD, Kullman G, Kvernebo K, Rosen L, Kroese A. Ultrasonographic screening for abdominal aortic aneurysm. Eur J Surg 1992; 158(10): 527-530.
6. van Laarhoven CJ, Borstlap AC, van Berge Henegouwen DP, Palmen FM, Verpalen MC, Schoemaker MC. Chronic obstructive pulmonary disease and abdominal aortic aneurysms. Eur J Vasc Surg 1993; 7(4): 386-390.
7. Simoni G, Pastorino C, Perrone R, Ardia A, Gianrossi R, Decian F et al. Screening for abdominal aortic aneurysms and associated risk factors in a general population. Eur J Vasc Endovasc Surg 1995; 10(2): 207-210.
8. Pleumeekers HJ, Hoes AW, van DE, van UH, Hofman A, de JPT et al. Aneurysms of the abdominal aorta in older adults. The Rotterdam Study. Am J Epidemiol 1995; 142(12): 1291-1299.
9. Naydeck BL, Sutton-Tyrrell K, Schiller KD, Newman AB, Kuller LH. Prevalence and risk factors for abdominal aortic aneurysms in older adults with and without isolated systolic hypertension. Am J Cardiol 1999; 83(5): 759-764.
10. Lederle FA, Johnson GR, Wilson SE, Chute EP, Littooy FN, Bandyk D et al. Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Ann Intern Med 1997; 126(6): 441-449.
11. Alcorn HG, Wolfson Jr. SK, Sutton Tyrrell K, Kuller LH, O'Leary D. Risk factors for abdominal aortic aneurysms in older adults enrolled in The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1996; 16(8): 963-970.
12. Norrgard O, Angquist KA, Johnson O. Familial aortic aneurysms: serum concentrations of triglyceride, cholesterol, HDL-cholesterol and (VLDL + LDL)-cholesterol. Br J Surg 1985; 72(2): 113-116.
13. Ross R. Atherosclerosis - an inflammatory disorder. N Engl J Med 1999; 340(2): 115-126.
14. Gorog P, Kovacs IB. Inhibition of vascular smooth muscle cell migration by intact endothelium is nitric oxide-mediated: interference by oxidised low density lipoproteins. J Vasc Res 1998; 35(3): 165-169.
15. Thompson RW, Parks WC. Role of matrix metalloproteinases in abdominal aortic aneurysms. Ann N Y Acad Sci 1996; 800: 157-174.
16. Sakalihasan N, Delvenne P, Nusgens BV, Limet R, Lapiere CM. Activated forms of MMP2 and MMP9 in abdominal aortic aneurysms. J Vasc Surg 1996; 24(1): 127-133.
17. Morris GE, Hubbard CS, Quick CR. An abdominal aortic aneurysm screening programme for all males over the age of 50 years. Eur J Vasc Surg 1994; 8(2): 156-160.
18. Rose G. The diagnosis of ischaemic heart disease and intermittent claudication in field surveys. Bull WHO 1962; 27: 645-658.
19. Fowkes FG, Housley E, Cawood EH, MacIntyre CC, Ruckley CV, Prescott RJ. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991; 20(2): 384-392.
20. Ellis M, Powell JT, Greenhalgh RM. Limitations of ultrasonography in surveillance of small abdominal aortic aneurysms. Br J Surg 1991; 78: 614-616.
21. Wilmink AB, Hubbard CS, Quick CR. Quality of the measurement of the infrarenal aortic diameter by ultrasound. J Med Screen 1997; 4(1): 49-53.
22. Singh K, Bonaa KH, Solberg S, Sorlie DG, Bjork L. Intra- and interobserver variability in ultrasound measurements of abdominal aortic diameter. The Tromso Study. Eur J Vasc Endovasc Surg 1998; 15(6): 497-504.
23. Garrett J. Stata Technical Bulletin Reprints 1995; 24: 161-165.
24. Wilmink ABM, Quick CRG. Epidemiology and potential for prevention of abdominal aortic aneurysm. Br J Surg 1998; 85: 155-162.
25. Franks P, Edwards R, Greenhalgh R, Powell J. Risk factors for abdominal aortic aneurysms in smokers. Eur J Vasc Endovasc Surg 1996; 11: 487-492.
26. Lederle FA, Johnson GR, Wilson SE, Chute EP, Hye RJ, Makaroun MS et al. The aneurysm detection and management study screening program: validation cohort and final results. Aneurysm Detection and Management Veterans Affairs Cooperative Study Investigators. Arch Intern Med 2000; 160(10): 1425-1430.
27. Lindholt JS, Heegaard NH, Vammen S, Fasting H, Henneberg EW, Heickendorff L. Smoking, but not lipids, lipoprotein(a) and antibodies against oxidised LDL, is correlated to the expansion of abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2001; 21(1): 51-56.
28. Brophy CM, Reilly JM, Smith GJ, Tilson MD. The role of inflammation in non specific abdominal aortic aneurysm disease. Ann Vasc Surg 1991; 5: 229-233.
29. Koch AE, Haines GK, Rizzo RJ, Radosevich JA, Pope RM, Robinson PG et al. Human abdominal aortic aneurysms. Immunophenotypic analysis suggesting an immune-mediated response. Am J Pathol 1990; 137(5): 1199-1213.
30. Salonen JT, Yla-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992; 339(8798): 883-887.
31. Cucina A, Pagliei S, Borrelli V, Corvino V, Stipa F, Cavallaro A et al. Oxidised LDL (OxLDL) induces production of platelet derived growth factor AA (PDGF AA) from aortic smooth muscle cells. Eur J Vasc Endovasc Surg 1998; 16(3): 197-202.
32. Hamilton CA. Low-density lipoprotein and oxidised low-density lipoprotein: their role in the development of atherosclerosis. Pharmacol Ther 1997; 74(1): 55-72.
33. Ganne F, Vasse M, Beaudeux JL, Peynet J, Francois A, Mishal Z et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes - a possible protective mechanism against atherothrombosis. Thromb Haemost 2000; 84(4): 680-688.
34. Zelvyte I, Dominaitiene R, Crisby M, Janciauskiene S. Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res 2002; 45(2): 147-154.
35. Vaughan CJ, Murphey MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996; 348: 1079-1082.
36. Nagashima H, Aoka Y, Sakomura Y, Sakuta A, Aomi S, Ishizuka N et al. A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. J Vasc Surg 2002; 36(1): 158-163.